NLRP1 and NLRP3 inflammasomes as a new approach to skin carcinogenesis (Review)
- Authors:
- Magdalena Ciążyńska
- Igor A. Bednarski
- Karolina Wódz
- Joanna Narbutt
- Aleksandra Lesiak
-
Affiliations: Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz 93‑513, Poland, Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz 91‑347, Poland, Laboratory of Molecular Biology, VET‑LAB, Brudzew 62‑720, Poland - Published online on: January 9, 2020 https://doi.org/10.3892/ol.2020.11284
- Pages: 1649-1656
-
Copyright: © Ciążyńska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kantono M and Guo B: Inflammasomes and cancer: The dynamic role of the inflammasome in tumor development. Front Immunol. 8:11322017. View Article : Google Scholar : PubMed/NCBI | |
|
Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, Dinarello CA and Fujita M: Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 285:6477–6488. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nasti TH and Timares L: Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage. Photochem Photobiol. 88:1111–1125. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rathinam VAK and Fitzgerald KA: Inflammasome complexes: Emerging mechanisms and effector functions. Cell. 165:792–800. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
de Zoete MR, Palm NW, Zhu S and Flavell RA: Inflammasomes. Cold Spring Harb Perspect Biol. 6:a0162872014. View Article : Google Scholar : PubMed/NCBI | |
|
Lamkanfi M: Emerging inflammasome effector mechanisms. Nat Rev Immunol. 11:213–220. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Martinon F, Burns K and Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Frew BC, Joag VR and Mogridge J: Proteolytic processing of Nlrp1b is required for inflammasome activity. PLoS Pathog. 8:e10026592012. View Article : Google Scholar : PubMed/NCBI | |
|
Nour AM, Yeung YG, Santambrogio L, Boyden ED, Stanley ER and Brojatsch J: Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages. Infect Immun. 77:1262–1271. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I and Reed JC: Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell. 25:713–724. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Van Opdenbosch N, Gurung P, Vande Walle L, Fossoul A, Kanneganti TD and Lamkanfi M: Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun. 5:32092014. View Article : Google Scholar : PubMed/NCBI | |
|
Guey B, Bodnar M, Manié SN, Tardivel A and Petrilli V: Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci USA. 111:17254–17259. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bauernfeind F and Ablasser A: Inflammasomes: Current understanding and open questions. Cell Mol Life Sci. 68:765–783. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Finger JN, Lich JD, Dare LC, Cook MN, Brown KK, Duraiswami C, Bertin J and Gough PJ: Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity. J Biol Chem. 287:25030–25037. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu CH, Moecking J, Geyer M and Masters SL: Mechanisms of NLRP1 mediated autoinflammatory disease in humans and mice. J Mol Biol. 430:142–152. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lamkanfi M and Dixit VM: Mechanisms and functions of inflammasomes. Cell. 157:1013–1022. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al: Non-canonical inflammasome activation targets caspase-11. Nature. 479:117–121. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L and Shao F: Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 514:187–192. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X and Lieberman J: A mechanistic understanding of pyroptosis: The fiery death triggered by invasive infection. Adv Immunol. 135:81–117. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao D, Wu Y, Zhuang J, Xu C and Zhang F: Activation of NLRP1 and NLRP3 inflammasomes contributed to cyclic stretch-induced pyroptosis and release of IL-1β in human periodontal ligament cells. Oncotarget. 7:68292–68302. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S and Beer HD: The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol. 17:1140–1145. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa T, Nakashima M and Suzuki Y: Nuclear DNA damage-triggered NLRP3 inflammasome activation promotes UVB-induced inflammatory responses in human keratinocytes. Biochem Biophys Res Commun. 477:329–335. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Strittmatter GE, Sand J, Sauter M, Seyffert M, Steigerwald R, Fraefel C, Smola S, French LE and Beer HD: IFN-γ primes keratinocytes for HSV-1-induced inflammasome activation. J Invest Dermatol. 136:610–620. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, Kresse S, Ruzicka T and Schauber J: HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res. 305:723–732. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ekman AK, Verma D, Fredrikson M, Bivik C and Enerbäck C: Genetic variations of NLRP1: susceptibility in psoriasis. Br J Dermatol. 171:1517–1520. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bivik C, Verma D, Winge MC, Lieden A, Bradley M, Rosdahl I and Söderkvist P: Genetic variation in the inflammasome and atopic dermatitis susceptibility. J Invest Dermatol. 133:2486–2489. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, McFann KK, Holland PJ, Fain PR, Dinarello CA and Spritz RA: NLRP1 haplo-types associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA. 110:2952e29562013. View Article : Google Scholar | |
|
Faustin B and Reed JC: Sunburned skin activates inflammasomes. Trends Cell Biol. 18:4–8. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Faustin B, Chen Y, Zhai D, Le Negrate G, Lartigue L, Satterthwait A and Reed JC: Mechanism of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: Loop domain-dependent suppression of ATP binding and oligomerization. Proc Natl Acad Sci USA. 106:3935–3940. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Reagan-Shaw S, Breur J and Ahmad N: Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes. Mol Cancer Ther. 5:418–429. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sand J, Haertel E, Biedermann T, Contassot E, Reichmann E, French LE, Werner S and Beer HD: Expression of inflammasome proteins and inflammasome activation occurs in human, but not in murine keratinocytes. Cell Death Dis. 9:242018. View Article : Google Scholar : PubMed/NCBI | |
|
Gurung P and Kanneganti TD: Autoinflammatory skin disorders: The inflammasome in focus. Trends Mol Med. 22:545–564. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu-Bryan R: Intracellular innate immunity in gouty arthritis: Role of NALP3 inflammasome. Immunol Cell Biol. 88:20–23. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shi F, Kouadir M and Yang Y: NALP3 inflammasome activation in protein misfolding diseases. Life Sci. 135:9–14. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA and Fujita M: Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol. 133:518–527. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells. Oncol Rep. 35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J and Yazdi AS: Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci. 109:18384–18389. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Melvin JC, Holmberg L, Rohrmann S, Loda M and Van Hemelrijck M: Serum lipid profiles and cancer risk in the context of obesity: Four meta-analyses. J Cancer Epidemiol. 2013:8238492013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA and Fujita M: NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 36:3820–3830. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong FL, Mamaï O, Sborgi L, Boussofara L, Hopkins R, Robinson K, Szeverényi I, Takeichi T, Balaji R, Lau A, et al: Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell. 167:187–202.e17. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll SM, Feldman ED, Turner EM and Alexander HR: The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res. 12:1088–1096. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pazyar N, Feily A and Yaghoobi R: An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 7:271–275. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
La E, Rundhaug JE and Fischer SM: Role of intracellular interleukin-1 antagonist in skin carcinogenesis. Mol Carcinog. 30:218–223. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bar D, Apte RN, Voronov E, Dinarello CA and Cohen S: A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 18:161–163. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
McKenzie RC, Oran A, Dinarello CA and Sauder DN: Interleukin-1 receptor antagonist inhibits subcutaneous B 16 melanoma growth in vivo. Anticancer Res. 16:437–441. 1996.PubMed/NCBI | |
|
Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Spiess PJ and Alexander HR: Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res. 63:5957–5961. 2003.PubMed/NCBI | |
|
Triozzi PL and Aldrich W: Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res. 30:345–354. 2010.PubMed/NCBI | |
|
Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA and Aizawa H: Role of proinflammatory cytokine IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol. 41:661–670. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW, Leinwand LA, et al: Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 21:686–698. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Twining CM, Sloane EM, Milligan ED, Chacur M, Martin D, Poole S, Marsh H, Maier SF and Watkins LR: Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain. 110:299–309. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Surguladze D, Deevi D, Claros N, Corcoran E, Wang W, Plym MJ, Wu Y, Doody J, Mauro DJ, Witte L, et al: Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res. 69:5643–5647. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Bi Z, Chu W and Wan Y: IL-1 receptor antagonist attenuates MAP kinase/AP-1 activation and MMP1 expression in UVA-irradiated human fibroblasts induced by culture medium from UVB-irradiated human skin keratinocytes. Int J Mol Med. 16:1117–1124. 2005.PubMed/NCBI | |
|
van de Veerdonk FL, Netea MG, Dinarello CA and Joosten LA: Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 32:110–116. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Abdelmeguid NE, Fakhoury R, Kamal SM and Al Wafai RJ: Effects of Nigella sativa and thymoquinone on biochemical and subcellular changes in pancreatic β-cells of streptozotocin-induced diabetic rats. J Diabetes. 2:256–266. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kanter M: Nigella sativa and derived thymoquinone prevents hippocampal neurodegeneration after chronic toluene exposure in rats. Neurochem Res. 33:579–588. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Woo CC, Kumar AP, Sethi G and Tan KH: Thymoquinone: Potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 83:443–451. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH and Mohammad RM: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 62:938–946. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmad I, Muneer KM, Tamimi IA, Chang ME, Ata MO and Yusuf N: Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol Appl Pharmacol. 270:70–76. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis LZ, Liu W, Luo Y, Okamoto M, Qu D, Dunn JH and Fujita M: Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun. 414:551–556. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, Hua KF, Chang WL, Huang JJ, Yang SS and Chen A: Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med. 51:744–754. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Han T, Liao J, Hu X, Xu S, Tian K, Gu X, Cheng K, Li Z, Hua H and Xu J: Oridonin, a promising ent-Kaurane diterpenoid lead compound. Int J Mol Sci. 17:E13952016. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Han T, Xu S, Zhou T, Tian K, Hu X, Cheng K, Li Z, Hua H and Xu J: Antitumor and antibacterial derivatives of oridonin: A main composition of Dong-Ling-Cao. Molecules. 21:E5752016. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Chen X, Qu S, Yao B, Xu Y, Wu J, Jin Y and Ma C: Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol Lett. 13:2838–2846. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XH, Zhang SF, Bao JT and Liu FY: Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. Tumour Biol. 39:10104283177016382017.PubMed/NCBI | |
|
Xia S, Zhang X, Li C and Guan H: Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 25:638–643. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Wang L, Zi Y, Zhang L, Guo Y and Huang Y: Oridonin effectively reverses the drug resistance of cisplatin involving induction of cell apoptosis and inhibition of MMP expression in human acute myeloid leukemia cells. Saudi J Biol Sci. 24:678–686. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HJ, Li D, Yang FY, Tashiro S, Onodera S and Ikejima T: Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res. 10:787–798. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Z, Wang X, Qi R, Wei L, Huo Y, Ma Y, Shi L, Chang Y, Li and Zhou L: Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of fatty acid synthase. Biochem Biophys Res Commun. 457:187–193. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
He H and Jiang Y: Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 9:25502018. View Article : Google Scholar : PubMed/NCBI |
